Knockdown of GLUT1 with GLUT1-shRNA, as well as inhibition of GLUT1 by anti-GLUT1 antibody, sensitizes HNSCC to cisplatin, providing another promising treatment strategy for chemoresistant HNSCC [39]. This evidence concerns the gene SLC2A1 and head and neck squamous cell carcinoma.